Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|2|229-237

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.2, 2014-01, pp. : 229-237

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 784-791

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression of E-Cadherin and Vascular Endothelial Growth Factor in Noncancerous Liver Is Associated with Recurrence of Hepatocellular Carcinoma after Curative Resection

By  

Oncology, Vol. 84, Iss. 1, 2013-02 ,pp. : 88-92

Karger

Access to resources Recommend Favorite

High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy

By  

Oncology, Vol. 81, Iss. 2, 2011-10 ,pp. : 98-103

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 91, Iss. 5, 2016-09 ,pp. : 261-266

Karger

Access to resources Recommend Favorite